The University of Texas MD Anderson Cancer Center, Houston, Texas (Y.T.S., W.D., Y.X., Y.S.).
Fred Hutchinson Cancer Center, Seattle, Washington (R.E.).
Ann Intern Med. 2021 May;174(5):602-612. doi: 10.7326/M20-2912. Epub 2021 Feb 9.
Breast density classification is largely determined by mammography, making the timing of the first screening mammogram clinically important.
To evaluate the cost-effectiveness of breast cancer screening strategies that are stratified by breast density.
Microsimulation model to generate the natural history of breast cancer for women with and those without dense breasts and assessment of the cost-effectiveness of strategies tailored to breast density and nontailored strategies.
Model parameters from the literature; statistical modeling; and analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Women aged 40 years or older.
Lifetime.
Societal.
No screening; biennial or triennial mammography from age 50 to 75 years; annual mammography from age 50 to 75 years for women with dense breasts at age 50 years and biennial or triennial mammography from age 50 to 75 years for those without dense breasts at age 50 years; and annual mammography at age 40 to 75 years for women with dense breasts at age 40 years and biennial or triennial mammography at age 50 to 75 years for those without dense breasts at age 40 years.
Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% annually.
RESULTS OF BASE-CASE ANALYSIS: Baseline screening at age 40 years followed by annual screening at age 40 to 75 years for women with dense breasts and biennial screening at age 50 to 75 years for women without dense breasts was effective and cost-effective, yielding an incremental cost-effectiveness ratio of $36 200 per QALY versus the biennial strategy at age 50 to 75 years.
At a societal willingness-to-pay threshold of $100 000 per QALY, the probability that the density-stratified strategy at age 40 years was optimal was 56% compared with 6 other strategies.
Findings may not be generalizable outside the United States.
The study findings advocate for breast density-stratified screening with baseline mammography at age 40 years.
National Cancer Institute.
乳腺密度分类主要由乳房 X 光摄影术决定,因此首次筛查乳房 X 光摄影术的时间在临床上非常重要。
评估基于乳腺密度分层的乳腺癌筛查策略的成本效益。
用于生成有和无致密乳腺女性乳腺癌自然史的微观模拟模型,并评估针对乳腺密度和非针对性策略量身定制的策略的成本效益。
文献中的模型参数;统计建模;和监测、流行病学和最终结果-医疗保险数据的分析。
年龄 40 岁或以上的女性。
终生。
社会。
不筛查;50 岁至 75 岁期间每两年或每三年进行一次乳房 X 光检查;50 岁时乳腺致密的女性每年进行一次乳房 X 光检查,50 岁时乳腺不致密的女性每两年或每三年进行一次乳房 X 光检查;40 岁至 75 岁期间,乳腺致密的女性每年进行一次乳房 X 光检查,40 岁时乳腺不致密的女性每两年或每三年进行一次乳房 X 光检查至 50 岁。
终生成本和质量调整生命年(QALYs),每年贴现 3%。
40 岁基线筛查,乳腺致密的女性 40 岁至 75 岁每年筛查,乳腺不致密的女性 50 岁至 75 岁每两年筛查一次,有效且具有成本效益,增量成本效益比为每 QALY 36200 美元,优于每两年在 50 岁至 75 岁之间进行的策略。
在 100000 美元/QALY 的社会意愿支付阈值下,40 岁时进行密度分层策略的概率为 56%,而不是其他 6 种策略。
研究结果可能不适用于美国以外的地区。
研究结果支持 40 岁时进行基于乳腺密度的筛查,并进行基线乳房 X 光检查。
美国国家癌症研究所。